Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-11-29

AUTHORS

Yosuke Hirotsu, Hiroshi Nakagomi, Kenji Amemiya, Toshio Oyama, Masayuki Inoue, Hitoshi Mochizuki, Masao Omata

ABSTRACT

HER2 (ERBB2) is an oncogene and 20% of breast cancers display HER2 amplification. The HER2 monoclonal antibody, trastuzumab, is used to treat breast cancers that display HER2 amplification, with good responses in 80–90% of cases; however, 10% of tumours develop resistance to trastuzumab. In this study, we collected data of primary breast cancer patients who treated at hospital during 2004–2014. In our cohort, 205 of 1497 primary breast cancer patients showed HER2-amplification, and 20 experienced recurrence after trastuzumab therapy. Of the 20 recurrent cases, only six patients had metastatic sites, excluding brain metastases, which were resistant to trastuzumab. To examine trastuzumab resistance in HER2-amplified breast cancer, we analysed clinical specimens before and after trastuzumab therapy. The results indicated that an intrinsic activating mutation leads to a valine-to-leucine substitution at codon 777 within the HER2 kinase domain (HER2 V777L). This was identified in one of six cases of a HER2-amplified breast cancer, both pre- and post-treatment; however, HER2 V777L was not identified in 14 responders who were treated with trastuzumab. These results suggest that HER2 V777L mutation is responsible for, and a predictive marker of, trastuzumab resistance. This is the first report to show that HER2 V777L is coincident with HER2-amplification in breast cancers that have developed trastuzumab resistance. More... »

PAGES

3

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12032-016-0857-2

DOI

http://dx.doi.org/10.1007/s12032-016-0857-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1005513585

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27900589


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trastuzumab", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Genome Analysis Center, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Genome Analysis Center, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hirotsu", 
        "givenName": "Yosuke", 
        "id": "sg:person.01104463136.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104463136.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Department of Breast Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakagomi", 
        "givenName": "Hiroshi", 
        "id": "sg:person.01152576336.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152576336.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pathology Division, Laboratory Department, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Genome Analysis Center, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan", 
            "Pathology Division, Laboratory Department, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Amemiya", 
        "givenName": "Kenji", 
        "id": "sg:person.01271466715.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271466715.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pathology Division, Laboratory Department, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Pathology Division, Laboratory Department, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oyama", 
        "givenName": "Toshio", 
        "id": "sg:person.011405362052.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011405362052.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Department of Breast Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inoue", 
        "givenName": "Masayuki", 
        "id": "sg:person.01354217107.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354217107.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Genome Analysis Center, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan", 
            "Department of Gastroenterology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mochizuki", 
        "givenName": "Hitoshi", 
        "id": "sg:person.01335140136.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335140136.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Genome Analysis Center, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan", 
            "Department of Gastroenterology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan", 
            "The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Omata", 
        "givenName": "Masao", 
        "id": "sg:person.0775700471.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775700471.08"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/ng.2822", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019741899", 
          "https://doi.org/10.1038/ng.2822"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12032-016-0744-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051585301", 
          "https://doi.org/10.1007/s12032-016-0744-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.2823", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010741940", 
          "https://doi.org/10.1038/ng.2823"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncomms9760", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031101673", 
          "https://doi.org/10.1038/ncomms9760"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.3037", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020182683", 
          "https://doi.org/10.1038/ng.3037"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature11412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024942368", 
          "https://doi.org/10.1038/nature11412"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-11-29", 
    "datePublishedReg": "2016-11-29", 
    "description": "HER2 (ERBB2) is an oncogene and 20% of breast cancers display HER2 amplification. The HER2 monoclonal antibody, trastuzumab, is used to treat breast cancers that display HER2 amplification, with good responses in 80\u201390% of cases; however, 10% of tumours develop resistance to trastuzumab. In this study, we collected data of primary breast cancer patients who treated at hospital during 2004\u20132014. In our cohort, 205 of 1497 primary breast cancer patients showed HER2-amplification, and 20 experienced recurrence after trastuzumab therapy. Of the 20 recurrent cases, only six patients had metastatic sites, excluding brain metastases, which were resistant to trastuzumab. To examine trastuzumab resistance in HER2-amplified breast cancer, we analysed clinical specimens before and after trastuzumab therapy. The results indicated that an intrinsic activating mutation leads to a valine-to-leucine substitution at codon 777 within the HER2 kinase domain (HER2 V777L). This was identified in one of six cases of a HER2-amplified breast cancer, both pre- and post-treatment; however, HER2 V777L was not identified in 14 responders who were treated with trastuzumab. These results suggest that HER2 V777L mutation is responsible for, and a predictive marker of, trastuzumab resistance. This is the first report to show that HER2 V777L is coincident with HER2-amplification in breast cancers that have developed trastuzumab resistance.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12032-016-0857-2", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094524", 
        "issn": [
          "1357-0560", 
          "1559-131X"
        ], 
        "name": "Medical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "keywords": [
      "breast cancer patients", 
      "primary breast cancer patients", 
      "breast cancer", 
      "trastuzumab resistance", 
      "cancer patients", 
      "trastuzumab therapy", 
      "HER2 amplification", 
      "HER2 monoclonal antibody", 
      "brain metastases", 
      "metastatic sites", 
      "HER2 kinase domain", 
      "predictive marker", 
      "recurrent cases", 
      "trastuzumab", 
      "patients", 
      "clinical specimens", 
      "cancer", 
      "monoclonal antibodies", 
      "HER2", 
      "V777L", 
      "good response", 
      "therapy", 
      "first report", 
      "mutations", 
      "recurrence", 
      "metastasis", 
      "leucine substitution", 
      "hospital", 
      "tumors", 
      "cohort", 
      "responders", 
      "cases", 
      "antibodies", 
      "resistance", 
      "kinase domain", 
      "markers", 
      "oncogene", 
      "report", 
      "amplification", 
      "response", 
      "study", 
      "valine", 
      "specimens", 
      "results", 
      "data", 
      "sites", 
      "substitution", 
      "domain"
    ], 
    "name": "Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient", 
    "pagination": "3", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1005513585"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12032-016-0857-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27900589"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12032-016-0857-2", 
      "https://app.dimensions.ai/details/publication/pub.1005513585"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-10T10:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_720.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12032-016-0857-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12032-016-0857-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12032-016-0857-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12032-016-0857-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12032-016-0857-2'


 

This table displays all metadata directly associated to this object as RDF triples.

215 TRIPLES      22 PREDICATES      87 URIs      73 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12032-016-0857-2 schema:about N3777d62616b54bd3ae07a46f8877f285
2 Na3d7b4e3de8d4378b3fb551a94048245
3 Na4da537106644dd28eaa16db1f48ca7a
4 Nbbc63547b15b42aba634304cdc815e7a
5 Nbf8b4d5c3f30407a8bf27e4687abd783
6 Nf9b3dd9b88ae4b5fa2e83a13fe58de3e
7 Nff83d4b638f84840888015df0b545de7
8 anzsrc-for:11
9 anzsrc-for:1112
10 schema:author Nf9e425c451ee44ddab9612a5cde21daa
11 schema:citation sg:pub.10.1007/s12032-016-0744-x
12 sg:pub.10.1038/nature11412
13 sg:pub.10.1038/ncomms9760
14 sg:pub.10.1038/ng.2822
15 sg:pub.10.1038/ng.2823
16 sg:pub.10.1038/ng.3037
17 schema:datePublished 2016-11-29
18 schema:datePublishedReg 2016-11-29
19 schema:description HER2 (ERBB2) is an oncogene and 20% of breast cancers display HER2 amplification. The HER2 monoclonal antibody, trastuzumab, is used to treat breast cancers that display HER2 amplification, with good responses in 80–90% of cases; however, 10% of tumours develop resistance to trastuzumab. In this study, we collected data of primary breast cancer patients who treated at hospital during 2004–2014. In our cohort, 205 of 1497 primary breast cancer patients showed HER2-amplification, and 20 experienced recurrence after trastuzumab therapy. Of the 20 recurrent cases, only six patients had metastatic sites, excluding brain metastases, which were resistant to trastuzumab. To examine trastuzumab resistance in HER2-amplified breast cancer, we analysed clinical specimens before and after trastuzumab therapy. The results indicated that an intrinsic activating mutation leads to a valine-to-leucine substitution at codon 777 within the HER2 kinase domain (HER2 V777L). This was identified in one of six cases of a HER2-amplified breast cancer, both pre- and post-treatment; however, HER2 V777L was not identified in 14 responders who were treated with trastuzumab. These results suggest that HER2 V777L mutation is responsible for, and a predictive marker of, trastuzumab resistance. This is the first report to show that HER2 V777L is coincident with HER2-amplification in breast cancers that have developed trastuzumab resistance.
20 schema:genre article
21 schema:inLanguage en
22 schema:isAccessibleForFree false
23 schema:isPartOf N175837482563471b8bbfafd8b1bfd8e8
24 Nfd48d96039af42709eb39eb72c451edf
25 sg:journal.1094524
26 schema:keywords HER2
27 HER2 amplification
28 HER2 kinase domain
29 HER2 monoclonal antibody
30 V777L
31 amplification
32 antibodies
33 brain metastases
34 breast cancer
35 breast cancer patients
36 cancer
37 cancer patients
38 cases
39 clinical specimens
40 cohort
41 data
42 domain
43 first report
44 good response
45 hospital
46 kinase domain
47 leucine substitution
48 markers
49 metastasis
50 metastatic sites
51 monoclonal antibodies
52 mutations
53 oncogene
54 patients
55 predictive marker
56 primary breast cancer patients
57 recurrence
58 recurrent cases
59 report
60 resistance
61 responders
62 response
63 results
64 sites
65 specimens
66 study
67 substitution
68 therapy
69 trastuzumab
70 trastuzumab resistance
71 trastuzumab therapy
72 tumors
73 valine
74 schema:name Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient
75 schema:pagination 3
76 schema:productId N5ff2982c895d47a9be4f526451bf93a2
77 N842c31fc339c422f80aa1f6e9633cc4e
78 Nec8d603eaefc449a873f2f1be0465816
79 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005513585
80 https://doi.org/10.1007/s12032-016-0857-2
81 schema:sdDatePublished 2022-05-10T10:13
82 schema:sdLicense https://scigraph.springernature.com/explorer/license/
83 schema:sdPublisher Nf7eadf5f79424665b62837da00d05642
84 schema:url https://doi.org/10.1007/s12032-016-0857-2
85 sgo:license sg:explorer/license/
86 sgo:sdDataset articles
87 rdf:type schema:ScholarlyArticle
88 N15bc56191305419982820ac36c91fb5d rdf:first sg:person.0775700471.08
89 rdf:rest rdf:nil
90 N175837482563471b8bbfafd8b1bfd8e8 schema:volumeNumber 34
91 rdf:type schema:PublicationVolume
92 N1a10e736cd7244b1bf4996640c6db201 rdf:first sg:person.01271466715.07
93 rdf:rest Nbf4e33f4bf0d4233bbceb6908a40ac98
94 N3777d62616b54bd3ae07a46f8877f285 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Breast Neoplasms
96 rdf:type schema:DefinedTerm
97 N5ff2982c895d47a9be4f526451bf93a2 schema:name doi
98 schema:value 10.1007/s12032-016-0857-2
99 rdf:type schema:PropertyValue
100 N842c31fc339c422f80aa1f6e9633cc4e schema:name dimensions_id
101 schema:value pub.1005513585
102 rdf:type schema:PropertyValue
103 Na3d7b4e3de8d4378b3fb551a94048245 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Middle Aged
105 rdf:type schema:DefinedTerm
106 Na4da537106644dd28eaa16db1f48ca7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Female
108 rdf:type schema:DefinedTerm
109 Nb78c1b8067094d22843f61a81f24af5a rdf:first sg:person.01335140136.50
110 rdf:rest N15bc56191305419982820ac36c91fb5d
111 Nbbc63547b15b42aba634304cdc815e7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Receptor, ErbB-2
113 rdf:type schema:DefinedTerm
114 Nbf4e33f4bf0d4233bbceb6908a40ac98 rdf:first sg:person.011405362052.18
115 rdf:rest Ne870779d73b64450bb672f98e4bec0f0
116 Nbf8b4d5c3f30407a8bf27e4687abd783 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Humans
118 rdf:type schema:DefinedTerm
119 Nd7cf0ae6f330487299f1d1091595f5b2 rdf:first sg:person.01152576336.53
120 rdf:rest N1a10e736cd7244b1bf4996640c6db201
121 Ne870779d73b64450bb672f98e4bec0f0 rdf:first sg:person.01354217107.78
122 rdf:rest Nb78c1b8067094d22843f61a81f24af5a
123 Nec8d603eaefc449a873f2f1be0465816 schema:name pubmed_id
124 schema:value 27900589
125 rdf:type schema:PropertyValue
126 Nf7eadf5f79424665b62837da00d05642 schema:name Springer Nature - SN SciGraph project
127 rdf:type schema:Organization
128 Nf9b3dd9b88ae4b5fa2e83a13fe58de3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Trastuzumab
130 rdf:type schema:DefinedTerm
131 Nf9e425c451ee44ddab9612a5cde21daa rdf:first sg:person.01104463136.69
132 rdf:rest Nd7cf0ae6f330487299f1d1091595f5b2
133 Nfd48d96039af42709eb39eb72c451edf schema:issueNumber 1
134 rdf:type schema:PublicationIssue
135 Nff83d4b638f84840888015df0b545de7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Drug Resistance, Neoplasm
137 rdf:type schema:DefinedTerm
138 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
139 schema:name Medical and Health Sciences
140 rdf:type schema:DefinedTerm
141 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
142 schema:name Oncology and Carcinogenesis
143 rdf:type schema:DefinedTerm
144 sg:journal.1094524 schema:issn 1357-0560
145 1559-131X
146 schema:name Medical Oncology
147 schema:publisher Springer Nature
148 rdf:type schema:Periodical
149 sg:person.01104463136.69 schema:affiliation grid-institutes:grid.417333.1
150 schema:familyName Hirotsu
151 schema:givenName Yosuke
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104463136.69
153 rdf:type schema:Person
154 sg:person.011405362052.18 schema:affiliation grid-institutes:grid.417333.1
155 schema:familyName Oyama
156 schema:givenName Toshio
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011405362052.18
158 rdf:type schema:Person
159 sg:person.01152576336.53 schema:affiliation grid-institutes:grid.417333.1
160 schema:familyName Nakagomi
161 schema:givenName Hiroshi
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152576336.53
163 rdf:type schema:Person
164 sg:person.01271466715.07 schema:affiliation grid-institutes:grid.417333.1
165 schema:familyName Amemiya
166 schema:givenName Kenji
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271466715.07
168 rdf:type schema:Person
169 sg:person.01335140136.50 schema:affiliation grid-institutes:grid.417333.1
170 schema:familyName Mochizuki
171 schema:givenName Hitoshi
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335140136.50
173 rdf:type schema:Person
174 sg:person.01354217107.78 schema:affiliation grid-institutes:grid.417333.1
175 schema:familyName Inoue
176 schema:givenName Masayuki
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354217107.78
178 rdf:type schema:Person
179 sg:person.0775700471.08 schema:affiliation grid-institutes:grid.26999.3d
180 schema:familyName Omata
181 schema:givenName Masao
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775700471.08
183 rdf:type schema:Person
184 sg:pub.10.1007/s12032-016-0744-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1051585301
185 https://doi.org/10.1007/s12032-016-0744-x
186 rdf:type schema:CreativeWork
187 sg:pub.10.1038/nature11412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024942368
188 https://doi.org/10.1038/nature11412
189 rdf:type schema:CreativeWork
190 sg:pub.10.1038/ncomms9760 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031101673
191 https://doi.org/10.1038/ncomms9760
192 rdf:type schema:CreativeWork
193 sg:pub.10.1038/ng.2822 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019741899
194 https://doi.org/10.1038/ng.2822
195 rdf:type schema:CreativeWork
196 sg:pub.10.1038/ng.2823 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010741940
197 https://doi.org/10.1038/ng.2823
198 rdf:type schema:CreativeWork
199 sg:pub.10.1038/ng.3037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020182683
200 https://doi.org/10.1038/ng.3037
201 rdf:type schema:CreativeWork
202 grid-institutes:grid.26999.3d schema:alternateName The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
203 schema:name Department of Gastroenterology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan
204 Genome Analysis Center, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan
205 The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
206 rdf:type schema:Organization
207 grid-institutes:grid.417333.1 schema:alternateName Department of Breast Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan
208 Department of Gastroenterology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan
209 Genome Analysis Center, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan
210 Pathology Division, Laboratory Department, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan
211 schema:name Department of Breast Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan
212 Department of Gastroenterology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan
213 Genome Analysis Center, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan
214 Pathology Division, Laboratory Department, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu, Yamanashi, Japan
215 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...